The main objective of this study is to investigate the effects of repetitive Transcranial
Magnetic Stimulation (rTMS) treatment on patients with probable early or moderate Alzheimer's
Device: rTMS active treatment
Device: rTMS sham treatment
We will connect you to the doctor responsible for this trial and help you get more information.
Locations near you
Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Full eligibility criteria for NCT02908815
Ages eligible for Study
55 Years and older
Genders eligible for Study
Accepts Healthy Volunteers
Individuals must have a MoCA score between 7 and 25, indicating mild cognitive impairment or dementia, a CDR score of 1-2, and a CSDD score of 18 or less.
Participants must have probable early or moderate Alzheimer's disease as confirmed by their treating neurologist, geriatrician, or psychiatrist, and/or by the study doctors.
Participants must be +55 years old.
Participants must be taking a stable dose of an acetylcholinesterase inhibitor for at least 3 months prior to study entry with no plans to change medication for the duration of the study. Or if participants decide to stop taking their Alzheimer's disease related medication, they must wait a minimum of 6 weeks prior to the start of the intervention.
Psychiatric conditions/disorders, or current neurological or medical disorders, other than AD, that could interfere with the subjects' cooperative participation (e.g. Severe agitation, prominent anxiety)
Impaired visual and auditory acuity that confounds performance in cognitive tests
Being diagnosed explicitly by other forms of dementia
Confounding psychiatric disorders (e.g., schizophrenia, bipolar affective disorder) or current neurological, systemic, or medical disorders (e.g., liver disease, congestive heart failure, severe COPD) that may impair cognition and/or could affect attention span.
Use of benzodiazepines or other hypnotics during the study and preceding two weeks
Use of drugs with anticholinergic properties
Participation in a clinical trial with any investigational agent within two weeks prior to study enrollment
Current alcohol abuse
History of epileptic seizures or epilepsy
Contraindication for receiving TMS treatment according to a TMS questionnaire.
Clinically significant abnormal laboratory findings which have not been approved by the Principal Investigator.
Inability to adequately communicate in English in Manitoba and Australia sites and either English or French in Montreal site.
Previous treatment with rTMS within the past 3 months
A change in medication for AD, mood disorders, or pain during the study.
All locations for NCT02908815
Melbourne, Victoria, Australia
Put me in touch!
Riverview Health Center
Winnipeg, Manitoba, Canada, R3L 2P4
Put me in touch!
Montreal, Quebec, Canada
Put me in touch!
View full eligibility
Tris trial is registered with FDA with number: NCT02908815. The sponsor of the trial is University of Manitoba and it is looking for 200 volunteers for the current phase.
Official trial title: Investigating the Effect of Repetitive Transcranial Magnetic Stimulation (rTMS) as a Treatment for Alzheimer's Disease
1What's a trial
4Get in touch
What's a trial
Not sure you're well informed about clinical trials? Learn more about their benefits, risks and other important details.
Enter your details like condition, age, gender and other preferences and we will show you a list of all relevant clinical trials.
Review the summary of the selected clinical trial and all the locations near you in order to see if it's of interest to you.
Get in touch
You've found an interesting trial? We'll need a bit more information about you so we can connect you to the doctor in charge.
Thank you for applying!
We'll contact you soon with more information.
Consult your doctor?
Some people want to consult their doctor before considering participation in a clinical trial. This is absolutely normal as your doctor should know your medical history and should be able to advise you. If you want you can easily share the information for this trial with your doctor by clicking on the button below.